1. Home
  2. AIM vs HOVR Comparison

AIM vs HOVR Comparison

Compare AIM & HOVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • HOVR
  • Stock Information
  • Founded
  • AIM 1966
  • HOVR 2013
  • Country
  • AIM United States
  • HOVR Canada
  • Employees
  • AIM N/A
  • HOVR N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • HOVR Blank Checks
  • Sector
  • AIM Health Care
  • HOVR Finance
  • Exchange
  • AIM Nasdaq
  • HOVR Nasdaq
  • Market Cap
  • AIM 15.9M
  • HOVR 17.6M
  • IPO Year
  • AIM N/A
  • HOVR N/A
  • Fundamental
  • Price
  • AIM $0.21
  • HOVR $0.90
  • Analyst Decision
  • AIM Strong Buy
  • HOVR Strong Buy
  • Analyst Count
  • AIM 2
  • HOVR 1
  • Target Price
  • AIM $2.75
  • HOVR $2.00
  • AVG Volume (30 Days)
  • AIM 672.1K
  • HOVR 3.6M
  • Earning Date
  • AIM 11-15-2024
  • HOVR 01-14-2025
  • Dividend Yield
  • AIM N/A
  • HOVR N/A
  • EPS Growth
  • AIM N/A
  • HOVR N/A
  • EPS
  • AIM N/A
  • HOVR 0.36
  • Revenue
  • AIM $190,000.00
  • HOVR N/A
  • Revenue This Year
  • AIM N/A
  • HOVR N/A
  • Revenue Next Year
  • AIM $1,693.10
  • HOVR N/A
  • P/E Ratio
  • AIM N/A
  • HOVR $2.47
  • Revenue Growth
  • AIM N/A
  • HOVR N/A
  • 52 Week Low
  • AIM $0.16
  • HOVR $0.24
  • 52 Week High
  • AIM $0.62
  • HOVR $3.29
  • Technical
  • Relative Strength Index (RSI)
  • AIM 50.86
  • HOVR 50.96
  • Support Level
  • AIM $0.19
  • HOVR $0.76
  • Resistance Level
  • AIM $0.23
  • HOVR $1.32
  • Average True Range (ATR)
  • AIM 0.02
  • HOVR 0.23
  • MACD
  • AIM -0.00
  • HOVR -0.04
  • Stochastic Oscillator
  • AIM 48.29
  • HOVR 18.49

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About HOVR New Horizon Aircraft Ltd.

New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and aiming to build a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, Floods and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.

Share on Social Networks: